Literature DB >> 19685281

Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay.

Hiromu Naruse1, Noriko Ikawa, Kiyoshi Yamaguchi, Yusuke Nakamura, Masami Arai, Chikashi Ishioka, Kokichi Sugano, Kazuo Tamura, Naohiro Tomita, Nagahide Matsubara, Teruhiko Yoshida, Yoshihiro Moriya, Yoichi Furukawa.   

Abstract

Lynch syndrome (hereditary non-polyposis colorectal cancer) is an inherited disease caused by germ-line mutation in mismatch repair genes such as MLH1, MSH2, and MSH6. The mutations include missense and nonsense mutations, small insertions and deletions, and gross genetic alterations including large deletions and duplications. In addition to these genetic changes, mutations in introns are also involved in the pathogenesis. However, it is sometimes difficult to interpret correctly the pathogenicity of variants in exons as well as introns. To evaluate the effect of splice-site mutations in two Lynch syndrome patients, we carried out a functional splicing assay using minigenes. Consequently, this assay showed that the mutation of c.1731+5G>A in MLH1 led to exon15 skipping, and that the mutation of c.211+1G>C in MSH2 created an activated cryptic splice-site 17-nucleotides upstream in exon1. These aberrant splicing patterns were not observed when wild type sequence was used for the assay. We also obtained concordant results by RT-PCR experiments with transcripts from the patients. Furthermore, additional functional splicing assays using two different intronic mutations described in earlier studies revealed splicing alterations that were in complete agreement with the reports. Therefore, functional splicing assay is helpful for evaluating the effects of genetic variants on splicing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19685281     DOI: 10.1007/s10689-009-9280-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  30 in total

1.  A nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families.

Authors:  A Stella; A Wagner; K Shito; S M Lipkin; P Watson; G Guanti; H T Lynch; R Fodde; B Liu
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

2.  Site directed mutagenesis of hMLH1 exonic splicing enhancers does not correlate with splicing disruption.

Authors:  P Lastella; N Resta; I Miccolis; A Quagliarella; G Guanti; A Stella
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

3.  RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.

Authors:  Andrew Sharp; Gabriella Pichert; Anneke Lucassen; Diana Eccles
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

4.  Ab initio prediction of mutation-induced cryptic splice-site activation and exon skipping.

Authors:  Petr Divina; Andrea Kvitkovicova; Emanuele Buratti; Igor Vorechovsky
Journal:  Eur J Hum Genet       Date:  2009-01-14       Impact factor: 4.246

5.  Improved splice site detection in Genie.

Authors:  M G Reese; F H Eeckman; D Kulp; D Haussler
Journal:  J Comput Biol       Date:  1997       Impact factor: 1.479

6.  Mutations in U6 snRNA that alter splice site specificity: implications for the active site.

Authors:  C F Lesser; C Guthrie
Journal:  Science       Date:  1993-12-24       Impact factor: 47.728

7.  Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing.

Authors:  S Syngal; E A Fox; C Li; M Dovidio; C Eng; R D Kolodner; J E Garber
Journal:  JAMA       Date:  1999-07-21       Impact factor: 56.272

8.  Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing.

Authors:  Michael Krawczak; Nick S T Thomas; Bernd Hundrieser; Matthew Mort; Michael Wittig; Jochen Hampe; David N Cooper
Journal:  Hum Mutat       Date:  2007-02       Impact factor: 4.878

9.  Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information.

Authors:  S M Hebsgaard; P G Korning; N Tolstrup; J Engelbrecht; P Rouzé; S Brunak
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

10.  In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5' splice sites.

Authors:  Kentaro Sahashi; Akio Masuda; Tohru Matsuura; Jun Shinmi; Zhujun Zhang; Yasuhiro Takeshima; Masafumi Matsuo; Gen Sobue; Kinji Ohno
Journal:  Nucleic Acids Res       Date:  2007-08-28       Impact factor: 16.971

View more
  5 in total

1.  Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome.

Authors:  Masanobu Takahashi; Yoichi Furukawa; Hideki Shimodaira; Masato Sakayori; Takuya Moriya; Yoshihiro Moriya; Yusuke Nakamura; Chikashi Ishioka
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

Review 2.  The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome.

Authors:  Juana V Martín-López; Richard Fishel
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 3.  Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review).

Authors:  Kouji Banno; Iori Kisu; Megumi Yanokura; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Int J Oncol       Date:  2012-06-25       Impact factor: 5.650

Review 4.  Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis.

Authors:  Natasha Caminsky; Eliseos J Mucaki; Peter K Rogan
Journal:  F1000Res       Date:  2014-11-18

5.  Splicing analysis for exonic and intronic mismatch repair gene variants associated with Lynch syndrome confirms high concordance between minigene assays and patient RNA analyses.

Authors:  Heleen M van der Klift; Anne M L Jansen; Niki van der Steenstraten; Elsa C Bik; Carli M J Tops; Peter Devilee; Juul T Wijnen
Journal:  Mol Genet Genomic Med       Date:  2015-04-23       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.